Foghorn Therapeutics Inc

-0.23 (-1.81%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)460.61M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.17 Million
Adjusted EPS-$0.63
See more estimates
10-Day MA$12.55
50-Day MA$12.65
200-Day MA$12.58
See more pivots

Foghorn Therapeutics Inc Stock, NASDAQ:FHTX

500 Technology Square, Suite 700, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.586.3100
Number of Employees: 95


Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.